1 August 2019 - Novartis Korea’s Revolade (eltrombopag olamine) will receive reimbursement for treating people with severe aplastic anaemia who have not shown sufficient response to immunosuppressive therapy, from next Monday.

Revolade treats thrombocytopenia, a rare condition where the patient has low blood platelet count.

Novartis Korea has also reduced the insurance price of Revolade 25 mg and 50 mg by 3.6%.

Read Korea Biomedical Review article